Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)
Quarterly Cash from Financing Activities fell 73.9% to $30.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $134.1 million through Mar 2026, down 23.41% year-over-year, with the annual reading at $233.9 million for FY2025, 279.56% up from the prior year.
Oculis Holding AG's Cash from Financing Activities history spans 5 years, with the latest figure at $30.1 million for Q1 2026.
- Cash from Financing Activities came in at $30.1 million for Q1 2026, down from $105.3 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $115.5 million in Q1 2025 to a low of -$2.1 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $30.2 million.
- Year-over-year, Cash from Financing Activities crashed 264.05% in 2024 and then skyrocketed 58848.04% in 2025.
- Oculis Holding AG's Cash from Financing Activities stood at -$288570.1 in 2022, then skyrocketed by 264.08% to $473488.9 in 2023, then skyrocketed by 549.73% to $3.1 million in 2024, then skyrocketed by 3324.12% to $105.3 million in 2025, then plummeted by 71.39% to $30.1 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Cash from Financing Activities are $30.1 million (Q1 2026), $105.3 million (Q4 2025), and -$2.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 30.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.14 Mn |
| Mar 31, 2026 | 30.14 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 730,773.59 |
| Jun 30, 2025 | 730,773.59 |
| Mar 31, 2025 | 115.49 Mn |
| Mar 31, 2025 | 115.49 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | -850,650.74 |
| Sep 30, 2024 | -850,650.74 |
| Jun 30, 2024 | 57.33 Mn |
| Jun 30, 2024 | 57.33 Mn |
| Mar 31, 2024 | 195,911.68 |
| Mar 31, 2024 | 195,911.68 |
| Dec 31, 2023 | 473,488.88 |
| Dec 31, 2023 | 473,488.88 |
| Sep 30, 2023 | 518,525.87 |
| Sep 30, 2023 | 518,525.87 |
| Jun 30, 2023 | 37.23 Mn |
| Jun 30, 2023 | 37.23 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Dec 31, 2022 | -288,570.09 |
| Dec 31, 2022 | -288,570.09 |
| Sep 30, 2022 | 2.03 Mn |
| Sep 30, 2022 | 2.03 Mn |